PMA device
Amvisc and Amvisc Plus Ophthalmic Viscosurgical Device (OVD)
Bausch & Lomb, Inc. · Aid, Surgical, Viscoelastic (LZP, Class III) · First FDA decision Dec 3, 2002, newest Jun 28, 2017Cataract
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
772
Naming "Amvisc"
MAUDE reports
68
Brand "Amvisc", since 2015
PubMed studies
34
Mentioning "Amvisc"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Amvisc and Amvisc Plus Ophthalmic Viscosurgical Device (OVD)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
P810025-S037 · Decided Jun 28, 2017 · 309 days after receipt · Normal 180 Day Track No User Fee
Device type: AID, SURGICAL, VISCOELASTIC (LZP) · Ophthalmology
- AMVISC AND AMVISC PLUS SODIUM HYALURONATE VISCOELASTICSPMA supplement
P810025-S021 · Decided Dec 3, 2002 · 207 days after receipt · Normal 180 Day Track
Device type: AID, SURGICAL, VISCOELASTIC (LZP) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Amvisc", any status and sponsor, newest update first.
- Hyaluronic Acid Barrier in ParotidectomyNot yet recruiting
Milton S. Hershey Medical CenterAcademic, hospital or other
NCT07941011 · 20 participants (planned) · Start Jan 1, 2027 · Primary completion Jan 31, 2029
Device: Axoguard HA+ Nerve Protector · For: Parotidectomy, Patient-reported Outcomes; Parotid Cancer; Parotid Gland Tumor and 2 more
- Halova Vaginal Ovules Versus Vaginal Estriol for Genitourinary Symptoms in Postmenopausal WomenCompleted
Perfect Care DistributionNot on our public-company list
NCT07932990 · 252 participants · Start Mar 7, 2025 · Primary completion Apr 22, 2026
Device: Halova vaginal ovules · For: Genitourinary Syndrome of Menopause (GSM); Vaginal Dryness; Vulvo Vaginal Atrophy (VVA)
Sites: Arad, Romania
- Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human SkinActive, not recruiting
University of MichiganAcademic, hospital or other
NCT06195605 · 15 participants (planned) · Start May 9, 2024 · Primary completion Nov 2027
Device: Restylane-L; Vehicle · For: Photoaging
Sites: Ann Arbor, Michigan
769 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Amvisc", and for the whole product code for context.
This brand
68 reports: 20 malfunction, 48 injury, 0 death
Whole product code LZP
1,607 reports: 550 malfunction, 1,056 injury, 0 death
Newest reports for this brand
0001313525-2026-00072 · Received Jun 18, 2026 · Event dated Feb 21, 2026
Device type: Aid, Surgical, Viscoelastic (LZP)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Endophthalmitis; Vitreous Floaters; Hypopyon; Loss of Vision; Eye Pain
0001313525-2026-00075 · Received Jun 18, 2026 · Event dated Mar 4, 2026
Device type: Aid, Surgical, Viscoelastic (LZP)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Macular Edema; Endophthalmitis; Visual Impairment; Vitreous Detachment
0001313525-2026-00079 · Received Jun 18, 2026 · Event dated May 6, 2026
Device type: Aid, Surgical, Viscoelastic (LZP)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Endophthalmitis; Hypopyon
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0110-04 · Started Oct 8, 2003 · Posted by FDA Nov 13, 2003
Reason given: Stability failure at the 20 month for viscosity specification
Cause as FDA categorized it: Other · Device type: Aid, Surgical, Viscoelastic (LZP)
Z-0111-04 · Started Oct 8, 2003 · Posted by FDA Nov 13, 2003
Reason given: Stability failure at the 20 month for viscosity specification
Cause as FDA categorized it: Other · Device type: Aid, Surgical, Viscoelastic (LZP)
Z-0112-04 · Started Oct 8, 2003 · Posted by FDA Nov 13, 2003
Reason given: Stability failure at the 20 month for viscosity specification
Cause as FDA categorized it: Other · Device type: Aid, Surgical, Viscoelastic (LZP)
1 more recall records with a free account
Published research
The most relevant PubMed records for "Amvisc"[tiab]. The summary above synthesizes these.
- Physical Characteristics, Clinical Application, and Side Effects of Viscoelastics in Ophthalmology.
Mohammadpour M, Asadigandomani H, Aminizade M, et al. · J Curr Ophthalmol · 2023Review
- Influence of ophthalmic viscosurgical devices on intraoperative aberrometry.
Masket S, Fram NR, Holladay JT · J Cataract Refract Surg · 2016Research Support, Non-U.S. Gov't
- Amvisc and Healon.
Alpar JJ · J Am Intraocul Implant Soc · 1984Comparative Study
- Thickness of the Protective Layers of Different Ophthalmic Viscosurgical Devices During Lens Surgery in a Porcine Model.
Wüst M, Matten P, Nenning M, et al. · Transl Vis Sci Technol · 2022
- [Intraocular pressure response after administration of 3 different viscoelastic agents after cataract operation].
Lüchtenberg M, Lüchtenberg C, Lang M, et al. · Ophthalmologe · 2000Clinical Trial, Comparative Study
- Viscoelastic adherence to corneal endothelium following phacoemulsification.
McDermott ML, Hazlett LD, Barrett RP, et al. · J Cataract Refract Surg · 1998Comparative Study, Research Support, Non-U.S. Gov't
- Amvisc in extracapsular cataract extraction.
Genstler DE, Keates RH · J Am Intraocul Implant Soc · 1983Comparative Study, Research Support, Non-U.S. Gov't
- Hydroxyl radical scavenging activity of a new ophthalmic viscosurgical device.
Maugeri F, Maltese A, Ward KW, et al. · Curr Eye Res · 2007
- Comparison of Healon and Amvisc.
Alpar JJ · Ann Ophthalmol · 1985Clinical Trial, Comparative Study
- Comparison of the properties of AMVISC and Healon.
Leith MM, Loftus SA, Kuo JW, et al. · J Cataract Refract Surg · 1987Comparative Study
- Viability of Descemet Membrane Endothelial Keratoplasty Grafts Folded in the Eye Bank.
Lohmeier J, Christy J, Chiang E, et al. · Cornea · 2018
- A prospective comparison of Amvisc and Healon in cataract surgery.
Sharpe ED, Simmons RJ · J Cataract Refract Surg · 1986Clinical Trial, Comparative Study
Other devices of this type
Also filed under product code LZP.
- PROVISC Ophthalmic Viscosurgical DeviceAlcon Research, Ltd. · PMA 2026
- Sodium Hyaluronate Ophthalmic Viscoelastic Devices (OVD)Johnson & Johnson Surgical Vision, Inc. · PMA 2024
- Amvisc & Amvisc Plus OvdBausch & Lomb, Inc. · PMA 2017
- Staarvisc II & Shellgel Sodium HyauronateAnika Therapeutics, Inc. · PMA 2012
- VISCOAT Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2026
- DISCOVISC Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2021
- Cellugel(R) Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2016
- Ocucoat (2% Hydroxpropylmethylcellulose Solution)Bausch & Lomb, Inc. · PMA 2012
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.